[1] SIEGEL R L,MILLER K D,WAGLE N S,et al.Cancer statistics,2023[J].CA Cancer J Clin，2023,73(1):17-48.
[2] FU Z,LI S,HAN S,et al.Antibody drug conjugate:the "biological missile" for targeted cancer therapy[J].Signal Transduct Target Ther,2022,7(1):93.
[3] LENÁRT S,LENÁRT P,ŠMARDA J,et al.Trop2:jack of all trades,master of none[J].Cancers(Basel),2020,12(11):3328.
[4] WEN Y,OUYANG D,ZOU Q,et al.A literature review of the promising future of TROP2:a potential drug therapy target[J].Ann Transl Med,2022,10(24):1403.
[5] SHVARTSUR A,BONAVIDA B.Trop2 and its overexpression in cancers:regulation and clinical/therapeutic implications[J].Genes Cancer,2015,6(3-4):84-105.
[6] GUERRA E,TREROTOLA M,ALOISI A L,et al.The Trop-2 signalling network in cancer growth[J].Oncogene,2013,32(12):1594-1600.
[7] ZHAO W,ZHU H,ZHANG S,et al.Trop2 is overexpressed in gastric cancer and predicts poor prognosis[J].Oncotarget,2016,7(5):6136-6145.
[8] ZHAO W,KUAI X,ZHOU X,et al.Trop2 is a potential biomarker for the promotion of EMT in human breast cancer[J].Oncol Rep,2018,40(2):759-766.
[9] MITO R,MATSUBARA E,KOMOHARA Y,et al.Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation[J].Pathol Int,2020,70(5):287-294.
[10] SIN S T K,LI Y,LIU M,et al.Down-regulation of TROP-2 predicts poor prognosis of hepatocellular carcinoma patients[J].Hepatol Commun,2018,2(11):1408-1414.
[11] WANG F,LIU X,YANG P,et al.Loss of TACSTD2 contributed to squamous cell carcinoma progression through attenuating TAp63-dependent apoptosis[J].Cell Death Dis,2014,5(3):e1133.
[12] ZENG P,CHEN M B,ZHOU L N,et al.Impact of TROP2 expression on prognosis in solid tumors:a systematic review and meta-analysis[J].Sci Rep,2016,6:33658.
[13] INAMURA K,YOKOUCHI Y,KOBAYASHI M,et al.Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes[J].Oncotarget,2017,8(17):28725-28735.
[14] SUN X,JIA L,WANG T,et al.Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment[J].J Cancer,2021,12(17):5310-5319.
[15] 陈兰,刘晓,陈小菊,等.自噬在肺癌靶向治疗耐药中作用的研究进展[J].现代医学,2021,49(4):470-474.
[16] BESSEDE A,PEYRAUD F,BESSE B,et al.TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer[J].Clin Cancer Res,2024,30(4):779-785.
[17] SYED Y Y.Sacituzumab govitecan:first approval[J].Drugs,2020,80(10):1019-1025.
[18] OCEAN A J,STARODUB A N,BARDIA A,et al.Sacituzumab govitecan(IMMU-132),an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers:safety and pharmacokinetics[J].Cancer,2017,123(19):3843-3854.
[19] BARDIA A,HURVITZ S A,TOLANEY S M,et al.Sacituzumab govitecan in metastatic triple-negative breast cancer[J].N Engl J Med,2021,384(16):1529-1541.
[20] RUGO H S,BARDIA A,MARME F,et al.Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-Negative metastatic breast cancer[J].J Clin Oncol,2022,40(29):3365-3376.
[21] TAGAWA S T,BALAR A V,PETRYLAK D P,et al.TROPHY-U-01:a phase Ⅱ open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors[J].J Clin Oncol,2021,39(22):2474-2485.
[22] HEIST R S,GUARINO M J,MASTERS G,et al.Therapy of advanced non-small-cell lung cancer with an SN-38-Anti-Trop-2 drug conjugate,sacituzumab govitecan[J].J Clin Oncol,2017,35(24):2790-2797.
[23] CHO B C,DOLS M C,CABANILLAS R R,et al.OA05.04 sacituzumab govitecan+pembrolizumab in 1L metastatic non-small cell lung cancer:preliminary results of the EVOKE-02 study[J].J Thorac Oncol,2023,18(11) Supplement:S54.
[24] OKAJIMA D,YASUDA S,MAEJIMA T,et al.Datopotamab deruxtecan,a novel TROP2-directed antibody-drug conjugate,demonstrates potent antitumor activity by efficient drug delivery to tumor cells[J].Mol Cancer Ther,2021,20(12):2329-2340.
[25] SHIMIZU T,SANDS J,YOH K,et al.First-in-human,phase Ⅰ dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-Directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer:TROPION-PanTumor01[J].J Clin Oncol,2023,41(29):4678-4687.
[26] GOTOY,SU W C,LEVY B P,et al.TROPION-Lung02:datopotamab deruxtecan(Dato-DXd) plus pembrolizumab(pembro) with or without platinum chemotherapy(Pt-CT) in advanced non-small cell lung cancer(aNSCLC)[J].J Clin Oncol,2023,41(16) Supplement:9004.
[27] PAPADOPOULOS K P,BRUNO D,KITAZONO S,et al.OA05.06 datopotamab deruxtecan(Dato-DXd)+durvalumab±carboplatin in advanced/mNSCLC:initial results from phase 1b TROPION-Lung04[J].J Thorac Oncol,2023,18(11) Supplement:S55.
[28] PAZ-ARES L,AHN M J,LISBERG A E,et al.1314MO TROPION-Lung05:datopotamab deruxtecan(Dato-DXd) in previously treated non-small cell lung cancer(NSCLC) with actionable genomic alterations(AGAs)[J].Ann Oncol,2023,34:S755-S756.
[29] AHN M J,LISBERG A,PAZ-ARES L,et al.LBA12 datopotamab deruxtecan(Dato-DXd) vs docetaxel in previously treated advanced/metastatic(adv/met) non-small cell lung cancer(NSCLC):results of the randomized phase Ⅲ study TROPION-Lung01[J].Ann Oncol,2023,34:S1305-S1306.
[30] CHENG Y,YUAN X,TIAN Q,et al.Preclinical profiles of SKB264,a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor,demonstrated promising antitumor efficacy compared to IMMU-132[J].Front Oncol,2022,12:951589.
[31] CHENG Y,CHEN Z,WANG W,et al.SKB264(TROP2-ADC) for the treatment of patients with advanced NSCLC:efficacy and safety data from a phase 2 study[J].J Clin Oncol,2023,41(16) Supplement:9114.
[32] YIN X,LI Y,WANG H,et al.Small cell lung cancer transformation:from pathogenesis to treatment[J].Semin Cancer Biol,2022,86(Pt 2):595-606.
[33] GRAY J E,HEIST R S,STARODUB A N,et al.Therapy of small cell lung cancer(SCLC) with a topoisomerase-Ⅰ-inhibiting antibody-drug conjugate(ADC) targeting Trop-2,sacituzumab govitecan[J].Clin Cancer Res,2017,23(19):5711-5719.
[34] BLACKHALL F,JAO K,GREILLIER L,et al.Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-High SCLC:results from the phase 3 TAHOE study[J].J Thorac Oncol,2021,16(9):1547-1558.
[35] MASTERS J C,NICKENS D J,XUAN D,et al.Clinical toxicity of antibody drug conjugates:a meta-analysis of payloads[J].Invest New Drugs,2018,36(1):121-135.
[36] PASSAROA,JÄNNE P A,PETERS S.Antibody-drug conjugates in lung cancer:recent advances and omplementing strategies[J].J Clin Oncol,2023,41(21):3747-3761. |
